Novartis & Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)

 Novartis & Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)

Novartis & Pfizer Enter into a Clinical Development Collaboration to Treat Non-Alcoholic Steatohepatitis (NASH)

Shots:

  • The agreement involves a clinical trial assessing Novartis’s tropifexor and Pfizer’s compounds, including PF-05221304, PF-06865571 & PF-06835919 for treatment of NASH
  • Novartis’ tropifexor (LJN452) is a Farnesoid X receptor (FXR) agonist indicated for NASH and has also received FTD by the US FDA for NASH with liver fibrosis in Oct, 2016
  • PF-05221304, PF-06865571 & PF-06835919 are inhibitors of Acetyl CoA-Carboxylase (ACC), Diacylglycerol O-Acyltransferase 2 (DGAT2) and Ketohexokinase (KHK) Inhibitor respectively. NASH has affected up to 6.5% of population WW, having no current treatment approved

Click here to read full press release/ article | Ref: Novartis | Image: News Utexas

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post